Wegovy is a registered trademark of Novo Nordisk A/S. It is a prescription medicine, and a licensed clinician must determine whether it is appropriate for an individual.
Important safety information: Wegovy has a boxed warning about the risk of thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma, or MTC, and in people with Multiple Endocrine Neoplasia syndrome type 2, or MEN 2. Serious risks include pancreatitis, gallbladder problems, low blood sugar with certain diabetes medicines, acute kidney injury related to dehydration, severe stomach problems, serious allergic reactions, diabetic retinopathy complications, increased heart rate, and pulmonary aspiration during anesthesia or deep sedation. Common side effects include nausea, diarrhea, vomiting, constipation, and stomach pain. Read the complete official Wegovy Prescribing Information and Medication Guide. A clinician should consider potential benefits and risks for each patient.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Medicare coverage depends on the route
There is no single Medicare and Wegovy answer that applies to every person. The prescribed use, the person's drug coverage, plan rules, and eligibility for a specific Medicare program all matter.
Federal law generally excludes drugs when used only for weight loss from the basic Part D benefit. Wegovy also has an FDA-approved use to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. CMS identifies that cardiovascular use as potentially coverable through the basic Part D benefit.
A Part D plan may still apply its formulary, prior authorization, quantity limit, and pharmacy network rules. The plan reviews the prescription and clinical information. A covered medical use does not assure that a specific claim will be approved or paid.
The temporary Medicare GLP-1 Bridge
CMS launched a separate Medicare GLP-1 Bridge for certain eligible people with Part D drug coverage. According to the official CMS information for Part D plans, the Bridge operates from July 1, 2026 through December 31, 2027.
The Bridge is not automatic coverage for all Medicare members. CMS sets clinical criteria, and the person must have an eligible type of Part D coverage. The prescriber must submit the required prior authorization information. CMS also explains that the Bridge operates outside the regular Part D benefit payment flow.
For an eligible Bridge prescription, CMS currently sets a $50 copay for a monthly supply. That is a program amount, not a general price promise. It applies only after the program confirms eligibility and approves the request.
If Wegovy is prescribed for a use that can be covered by the basic Part D benefit, such as its qualifying cardiovascular risk-reduction use, CMS says that prescription does not qualify for Bridge coverage. The Part D plan's regular review process applies instead.
The Medicare.gov weight-loss drug page provides a patient-facing overview of Bridge criteria and directs members to current help. Because rules and participating products can change, confirm the details before each enrollment or plan year.
Questions to ask your plan
Call the number on the Medicare drug plan member card. Ask the representative to review the exact drug, dosage form, prescribed use, and pharmacy.
Useful questions include:
- Should this request go through my basic Part D benefit or the Medicare GLP-1 Bridge?
- What clinical documentation and prior authorization form are required?
- Is the prescribed product on the formulary?
- Are there quantity limits or step requirements?
- Which local or mail-order pharmacies are in network or preferred?
- What would I owe if the request is approved?
- How do I request a written decision or appeal an adverse decision?
Keep the date, representative's name, and call reference number. An estimate is not a final coverage decision. Written plan or program information is more useful if an answer later changes.
Commercial savings cards are different
Manufacturer commercial savings offers generally exclude people enrolled in federal health care programs. The manufacturer’s official Wegovy cost and coverage page states that government beneficiaries are excluded from its commercial savings offer.
That commercial offer is separate from the federal Bridge. A person should not submit a commercial savings card with a Medicare claim unless the current official terms clearly allow it. Ask the pharmacy which payment route it is using before paying.
A cash purchase outside Medicare may not count toward Part D spending totals. Confirm that consequence with the plan before choosing self-pay.
Body Good coverage support and fees
Body Good may provide coverage support, such as benefit checks and assistance with plan-requested clinical paperwork. Approval and payment are determined by the Part D plan, CMS program, or other payer, not by Body Good. No service can promise a favorable coverage result.
Body Good's prices are service fees for the clinical program described during intake. They are not Medicare drug copays, are not the price of medication, and are not a quote for any individual. Eligibility is determined by a clinician.
Medication cost is separate and is not included in a Body Good service fee. The dispensing pharmacy or another authorized provider charges for medication. Medicare coverage of a prescription does not establish coverage of a Body Good service fee. Review each charge separately.
Clinical review still comes first
Medicare eligibility and clinical eligibility answer different questions. A coverage pathway does not mean the medicine is safe or appropriate for a particular person. A licensed clinician must review medical history, current medicines, contraindications, and risks before deciding whether to prescribe.
A prescription is not guaranteed. If prescribed, ongoing care may include monitoring for side effects, response, and changes in health. Urgent or severe symptoms require prompt medical attention, not a coverage-support conversation.
This website provides information and a pricing overview. It takes no payment, collects no protected health information, and runs no intake form. Intake and checkout happen on joinbodygood.com.
Frequently asked questions
Does every Medicare member qualify for the GLP-1 Bridge?
No. CMS applies plan-enrollment and clinical criteria, and prior authorization is required. The Bridge also does not replace basic Part D review for uses already coverable under Part D.
Is the Bridge copay part of regular Part D spending?
CMS says the Bridge operates outside the Part D benefit payment flow, and its copay does not count toward Part D true out-of-pocket costs. Confirm current rules with Medicare or the plan.
Can Body Good determine whether Medicare approves my request?
No. Body Good can provide coverage support, but the plan or program makes the decision. Start the Body Good clinical intake if you want to request an individual evaluation.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.